What is LOPJLB’s current signal on DNTH?

LOPJLB’s latest quantitative signal on Dianthus Therapeutics, Inc. (DNTH) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is DNTH in?

Dianthus Therapeutics, Inc. (DNTH) is currently classified in the CRISIS HMM market regime on LOPJLB.

Where is Dianthus Therapeutics, Inc. based / listed?

Dianthus Therapeutics, Inc. is based in US, listed on NASDAQ.

Dianthus Therapeutics, Inc. (DNTH)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$82.37-0.07%Close

SELLCRISIS · day 13

RANGE

DATA 2026-10-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $3.4B
Beta: 0.08
P/E (TTM): -656.92

Short % float: 31.35%
Days to cover: 8.3
SI change: +3.5%

1W: -6.62%
1M: -20.25%

vs SPY 1W: -7.78%
vs SPY 1M: -23.24%

Industry peers

FMP comparable companies · ranked by market cap

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved…

Employees: 92
Headquarters: US
Founded: 2018
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 41.8M
Float: 69.8%

dianthustx.com ↗

Key executives

Marino Garcia — President, Chief Executive Officer & Director

Simrat Randhawa — Executive Vice President and Head of R&D

Ryan Savitz — Executive VP, CFO, Chief Business Officer & Treasurer

SEC filings

EDGAR · CIK 16905850 · DNTH

Analyst consensus

Buy

Bullish11100.0%

Neutral00.0%

Bearish00.0%

L $120.00Avg $132.60H $158.00

Target$132.60+60.98%

Last$82.37

Key stats

Industry peers

Prediction markets

Company news